Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.55 |
| ▸ | NPC1 | O15118 | 7/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | GLA | P06280 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3900333 | 1.00 | KDM4E (0.55) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL6850817 | 0.86 | KDM4E (0.56) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL6850810 | 0.86 | KDM4E (0.56) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL13722766 | 0.81 | KDM4E (0.50) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL6022618 | 0.80 | KDM4E (0.52) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL6022622 | 0.80 | KDM4E (0.52) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL6156973 | 0.79 | KDM4E (0.60) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL6156977 | 0.79 | KDM4E (0.60) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL6877010 | 0.76 | KDM4E (0.56) | KDM4ENPC1RAB9AMAPTGLA | |
| SCHEMBL6877002 | 0.76 | KDM4E (0.56) | KDM4ENPC1RAB9AMAPTGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501846-B1 | TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS | ABBOTT LAB (US) | 2009-03-18 | — | — | EP | disclosed |
| US-6992069-B2 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2006-01-31 | — | — | US | disclosed |
| US-20040029818-A1 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029818-A1 | Tricyclic macrolide antibacterial compounds | RPN1, CASP1, MRPL21 | KDM4E 4677/4885NPC1 9/4885RAB9A 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.